Risperdal

Irritability, Autism, Schizophrenia + 10 more

Treatment

6 FDA approvals

20 Active Studies for Risperdal

What is Risperdal

Risperidone

The Generic name of this drug

Treatment Summary

Risperidone is a medication used to treat mental health conditions like schizophrenia and bipolar disorder. It is a type of antipsychotic medication that works by blocking certain chemical receptors in the brain, reducing the overactivity of certain pathways. Risperidone binds very strongly to certain receptors in the brain, and has lesser activity at other targets which may contribute to side effects.

Risperidone

is the brand name

image of different drug pills on a surface

Risperdal Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Risperidone

Risperidone

1993

522

Approved as Treatment by the FDA

Risperidone, also known as Risperidone, is approved by the FDA for 6 uses such as Bipolar 1 Disorder and Acute Mania .

Bipolar 1 Disorder

Acute Mania

Mixed manic depressive episode

Common Cold

Bipolar Disorder

Bipolar Disorder

Effectiveness

How Risperdal Affects Patients

Risperidone works by reducing the activity of certain chemicals in the brain like dopamine and serotonin. It does this by attaching itself to certain receptors in the brain, with a higher binding affinity for serotonin receptors than dopamine receptors. This makes it different from other antipsychotic drugs which tend to attach more strongly to dopamine receptors. This difference is thought to be the reason why risperidone causes fewer side effects than its predecessors.

How Risperdal works in the body

Risperidone works by stopping too much dopamine and serotonin from being released in the brain. Excess dopamine and serotonin can cause delusions, hallucinations and other symptoms of schizophrenia. Risperidone is able to block these receptors for a short time, reducing the amount of dopamine and serotonin in the brain. This helps to reduce the symptoms of schizophrenia without causing side effects. Risperidone also blocks other receptors such as alpha-1, alpha-2, and histamine, which may also help reduce symptoms of schizophrenia, though the exact mechanism of action is not yet known.

When to interrupt dosage

The measure of Risperdal is contingent upon the determined issue, including Psychotic Disorders, Irritability and Acute Mania. The quantity of dosage changes, as per the procedure of delivery (e.g. Subcutaneous or Solution) presented in the table below.

Condition

Dosage

Administration

Autism

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Schizophrenia

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Acute Coryza

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Schizophrenia

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Bipolar Disorder

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Behcet Syndrome

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Alzheimer's Disease

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Common Cold

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Schizophrenia

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

responsive to first treatment

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Irritability

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Psychotic Disorders

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Bipolar Disorder

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Warnings

Risperdal has two contraindications. It should not be taken when encountering any of the conditions listed in the following table.

Risperdal Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Risperidone may interact with Pulse Frequency

There are 20 known major drug interactions with Risperdal.

Common Risperdal Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Alfuzosin

Major

Risperidone may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Risperidone may increase the antipsychotic activities of Amisulpride.

Aripiprazole

Major

Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Aripiprazole lauroxil

Major

Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.

Risperdal Toxicity & Overdose Risk

Overdosing on Levetiracetam can cause fatigue, body spasms, rapid heart rate, slow heart rate, and seizures. The lethal dose in rats is 57.7 mg/kg if given orally or 34 mg/kg if given intravenously.

image of a doctor in a lab doing drug, clinical research

Risperdal Novel Uses: Which Conditions Have a Clinical Trial Featuring Risperdal?

359 active studies are currently being conducted to evaluate the potential of Risperdal to provide relief from Acute Mania, Bipolar Disorder and Autism.

Condition

Clinical Trials

Trial Phases

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Schizophrenia

32 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Schizophrenia

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Irritability

8 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Psychotic Disorders

0 Actively Recruiting

Acute Coryza

1 Actively Recruiting

Not Applicable

Common Cold

0 Actively Recruiting

Autism

7 Actively Recruiting

Phase 2, Not Applicable

Bipolar Disorder

0 Actively Recruiting

Alzheimer's Disease

15 Actively Recruiting

Not Applicable, Phase 2, Phase 1

responsive to first treatment

0 Actively Recruiting

Risperdal Reviews: What are patients saying about Risperdal?

4

Patient Review

2/13/2022

Risperdal for Bipolar Disorder in Remission

I definitely notice a difference in my mood stability when I'm on this medication. Without it, I tend to swing to more extreme emotions; however, while on the medication, I feel much more even-keeled.

4

Patient Review

8/13/2022

Risperdal for Schizophrenia

It can be tough to keep my eyes open on this medication, but I've gotten used to it. The only other downside is that sidewalk walking and being around cars can be dangerous if my eyes close for even a few seconds. But overall, this med works great for my schizophrenia.

4

Patient Review

9/4/2019

Risperdal for Bipolar Disorder in Remission

I felt a little dizzy on the first day taking risperidone, but that went away quickly. After a month of taking it, I've noticed my focus and concentration have improved significantly. The only downside is that I feel a little tired, but it's not too bad.

4

Patient Review

8/13/2022

Risperdal for Schizophrenia

It can be tough to keep my eyes open when I'm on this medication, but I've gotten used to it. The main thing is that it really helps with my schizophrenia.

4

Patient Review

9/4/2019

Risperdal for Bipolar Disorder in Remission

I felt a little dizzy after taking the medication the first day, but that went away. I've been on it for 4 weeks now and have definitely noticed an improvement in my focus and concentration. The medicine makes me feel a little tired, but it's not too bad.

4

Patient Review

2/13/2022

Risperdal for Bipolar Disorder in Remission

Before taking this medication, my mood swings were really severe. Now that I'm on it, I don't feel those extremes as much. It's helped me a lot.

3.7

Patient Review

11/3/2022

Risperdal for Bipolar Disorder in Remission

While this medication was effective in treating my schizophrenia, it unfortunately also rendered me infertile. In 12 years of use, I have tried to impregnate 100 ladies and have been unsuccessful. This is a serious fertility problem for males.

3.7

Patient Review

3/19/2022

Risperdal for Additional Medications to Treat Depression

This helps me a lot with my anxiety but I sometimes find the drowsy side effects tough to manage.

3.7

Patient Review

4/30/2022

Risperdal for Additional Medications to Treat Depression

I find it hard to wakeup in the next morning when I'm taking this drug at night. But it improved my condition to better.

3.7

Patient Review

11/3/2022

Risperdal for Bipolar Disorder in Remission

While this medication was successful in treating my schizophrenia, I unfortunately experienced serious fertility problems as a result of taking it. In twelve years, I tried to impregnate one hundred ladies and was unsuccessful.

3.7

Patient Review

3/19/2022

Risperdal for Additional Medications to Treat Depression

This drug does a great job at helping me manage my anxiety. The only downside is that I sometimes feel really drowsy as a result of taking it.

3.7

Patient Review

4/30/2022

Risperdal for Additional Medications to Treat Depression

I find it hard to wakeup in the next morning when I'm taking this drug at night. But it improved my condition overall.

3

Patient Review

10/9/2022

Risperdal for Bipolar Depression

I switched to Risperidone recently after taking Lamictal for six years. I'm glad to be off of Lamictal, but I find that Risperidone has made me feel emotionless and unmotivated. My anxiety has also increased since starting this medication, so I may ask my doctor to switch me back.

3

Patient Review

10/9/2022

Risperdal for Bipolar Depression

I switched to Risperidone from Lamictal, and while I'm glad to be off of the latter, I feel much worse on the former. I don't laugh anymore, anxiety has increased, and generally speaking I just have zero motivation. Going to speak with my doctor about getting off of it soon.

2.7

Patient Review

10/14/2022

Risperdal for Bipolar Depression

This medicine made me feel incredibly lethargic and uncoordinated. I would definitely not recommend it to anyone.

2.7

Patient Review

4/26/2019

Risperdal for Bipolar I Disorder with Most Recent Episode Mixed

I just started taking this medication and I'm coming off Abilify. I've been taking it for 3 days and so far, I had a very deep sleep last night but the first night I had insomnia. I'm starting to feel a little sedated. Will come back to review it when I've taken it for a longer period of time.

2.7

Patient Review

10/14/2022

Risperdal for Bipolar Depression

This medicine made me feel awful. I felt like I needed to stay in bed all day and could hardly function. The dizziness and muscle jerks were really unpleasant.

2.7

Patient Review

4/26/2019

Risperdal for Bipolar I Disorder with Most Recent Episode Mixed

I'm just starting to take this medication, and so far I've had one good night's sleep and one bad night's sleep. I'm also feeling a little sedated during the day. I'll come back and update my review after taking it for a longer period of time. Right now, I'm concerned about potential weight gain side effects that I've read about online.

2.3

Patient Review

5/26/2022

Risperdal for Bipolar Depression

I wouldn't recommend this to someone who struggles with anxiety on a daily basis, as it unfortunately worsened my anxiety and caused me to have panic attacks. It did help take away the sharp edges of emotions, but for me it wasn't worth the increased anxiety in return.

2.3

Patient Review

5/26/2022

Risperdal for Bipolar Depression

I would not recommend this to people who already suffer from anxiety. It unfortunately made my anxiety worse and I began having panic attacks every day. While it did help me think more clearly, the increased anxiety was not worth the trade-off.

2.3

Patient Review

7/28/2022

Risperdal for Additional Medications to Treat Depression

The medicine increased my anxiety and restlessness to an almost unbearable level.

2.3

Patient Review

7/28/2022

Risperdal for Additional Medications to Treat Depression

This medication unfortunately made my anxiety and restlessness much worse.

2

Patient Review

5/5/2021

Risperdal for Mania associated with Bipolar Disorder

I was only on a low dose, but it made me so dizzy and sick that I couldn't even stand up.

2

Patient Review

5/5/2021

Risperdal for Mania associated with Bipolar Disorder

I didn't have a good experience with this medication. I was on a low dose (.5 mg) but it made me so dizzy and sick that I couldn't even stand up or keep anything down.

2

Patient Review

3/6/2019

Risperdal for Mania associated with Bipolar Disorder

2

Patient Review

3/6/2019

Risperdal for Mania associated with Bipolar Disorder

1

Patient Review

9/25/2019

Risperdal for Mania associated with Bipolar Disorder

I started taking this medication when I was 15 and it worked well for a while, but after six years I started feeling my symptoms come back. I decided to try lithium as well and it has been working wonders!

1

Patient Review

9/25/2019

Risperdal for Mania associated with Bipolar Disorder

I started taking this when I was 15 and it worked well for the first few years, but then I began to feel my symptoms coming back. I've been on lithium as well for the past year and I haven't felt this good ever! Definitely recommend these two medications combined.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about risperdal

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the side effect of Risperdal?

"To minimize dizziness and lightheadedness, get up slowly from a sitting or lying position.

Drowsiness, dizziness, lightheadedness, drooling, nausea, weight gain, or tiredness may occur. These effects can persist or worsen- tell your doctor or pharmacist promptly. Dizziness and lightheadedness can increase the risk of falling, so get up slowly when rising from a sitting or lying position."

Answered by AI

What is the drug Risperdal used for?

"This medication is used to treat conditions such asschizophrenia, bipolar disorder, or autism-related irritability. It is not to be used for behavioral issues in adults with dementia. A prescription from a doctor is required to obtain this medication."

Answered by AI

Is Risperdal a Xanax?

"Risperdal is usually given to people with schizophrenia, bipolar mania, and autism. Xanax is mostly given to people who have panic attacks and anxiety disorders. Risperdal and Xanax work differently and are not in the same drug class."

Answered by AI

How does Risperdal make you feel?

"It can take several days or even months for risperidone to work. Common side effects include feeling sleepy, problems with your movement and headaches. You may also feel more hungry than usual, which can lead to weight gain."

Answered by AI

Clinical Trials for Risperdal

Image of Cumberland Medical Center in Crossville, United States.

Quest AD-Detect Blood Test for Alzheimer's Disease

60 - 90
All Sexes
Crossville, TN

The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio

Recruiting
Has No Placebo

Cumberland Medical Center (+5 Sites)

Samuel Moore, MD

Have you considered Risperdal clinical trials?

We made a collection of clinical trials featuring Risperdal, we think they might fit your search criteria.
Go to Trials
Image of Wellstar MCG Hospital, Neurology Memory Clinic in Augusta, United States.

Deep Brain Stimulation for Alzheimer's Disease

65 - 85
All Sexes
Augusta, GA

The purpose of this study is to test a new procedure to treat Alzheimer's disease. The procedure is called intermittent Deep Brain Stimulation (DBS) of the nucleus basalis of Meynert. There will be up to six participants enrolled at Wellstar MCG Memory Clinic. There will be another six participants similarly enrolled to act as a control group that does not receive DBS. This second group will document the course of progression of Alzheimer's disease under the normal standard of care. The main goal of the study is to determine if DBS can sustain or improve cognition in Alzheimer's disease for at least two years. Participant data, with identifying information removed, may be shared with online repositories for comparison with trials with similar subjects.

Phase 1
Waitlist Available

Wellstar MCG Hospital, Neurology Memory Clinic

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Multimodal Intervention for Bipolar Disorder

18 - 35
All Sexes
Hamilton, Canada

People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment. Although clinical guidelines recommend combining medication and psychosocial support, and research shows that early intervention is associated with improved outcomes, no structured care programs currently exist for individuals in the early stages of BD, contributing to chronic illness progression and preventable hospitalizations. This open-label pilot trial will assess the feasibility, acceptability, and preliminary effectiveness of a structured care pathway to support the transition from hospital to community care. The intervention includes group-based psychoeducation, individual peer support, and personalized support for community healthcare providers to improve illness insight, treatment adherence, and symptom management.

Waitlist Available
Has No Placebo

St. Joseph's Healthcare Hamilton

Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Brain Stimulation for Cannabis Craving in Schizophrenia

18 - 65
All Sexes
Nashville, TN

The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder. This is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis. Aim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100). Aim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100). As an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.

Waitlist Available
Has No Placebo

Vanderbilt Psychiatric Hospital

Have you considered Risperdal clinical trials?

We made a collection of clinical trials featuring Risperdal, we think they might fit your search criteria.
Go to Trials
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN

The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.

Waitlist Available
Has No Placebo

Vanderbilt Psychiatric Hospital

Heather Ward, MD

Image of Woodland International Research Group /ID# 275747 in Little Rock, United States.

Emraclidine for Schizophrenia

18 - 65
All Sexes
Little Rock, AR

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Phase 2
Recruiting

Woodland International Research Group /ID# 275747 (+6 Sites)

ABBVIE INC.

AbbVie

Have you considered Risperdal clinical trials?

We made a collection of clinical trials featuring Risperdal, we think they might fit your search criteria.
Go to Trials